What is the 13F Pro Quality Score for BMY?

13F Pro ranks BRISTOL MYERS SQUIBB CO (BMY) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View BMY's current score at https://13fpro.ai/company/BMY (free sign-up required for the full ranking).

Which hedge funds own the most BMY stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of BMY include BlackRock,, VANGUARD CAPITAL MANAGEMENT, STATE STREET. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/BMY as soon as new 13F filings post.

Where does 13F Pro source BMY data?

All BRISTOL MYERS SQUIBB CO fundamentals and ownership data come directly from SEC EDGAR. BRISTOL MYERS SQUIBB CO files with the SEC under CIK 14272. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is BMY in?

BRISTOL MYERS SQUIBB CO (BMY) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives BMY's revenue?

Per BRISTOL MYERS SQUIBB CO's latest 10-Q filed with the SEC on 2026-07-30, the biggest revenue drivers are: Growth Portfolio ($7,560M, +15% YoY); Legacy Portfolio ($5,422M, -4% YoY); Eliquis ($4,481M, +22% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/BMY.

What are BMY's largest expenses?

BRISTOL MYERS SQUIBB CO's latest 10-Q reports these as the largest expense items: Cost of products sold ($3,726M, +11% YoY); Research and development ($2,959M, +15% YoY); Selling, general and administrative ($1,826M, +7% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is BMY research updated on 13F Pro?

BMY's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

BRISTOL MYERS SQUIBB CO(BMY)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSElarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 14272 BMY stock profile & AI dashboard →

13F Pro Quality Score

70.4/100

Rank #219 of 2,961 stocksTOP 10%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

34.9/100

Profitability

82.5/100

Balance Sheet

85.5/100

Earnings Quality

72.1/100

Free Cash Flow

77.0/100

Institutional Flow

73.8/100

Revenue Scale

96.8/100

Dilution Risk

53.3/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why BMY Scores 70/100

exact factor attribution · 2026-09-11

BMY's composite is driven by scale and profitability, held back by revenue growth. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Scale

+7.0 pts

97th pct

Profitability

+4.9 pts

83th pct

Free cash flow

+4.0 pts

77th pct

Capital efficiency

+3.5 pts

86th pct

Earnings quality

+2.2 pts

72th pct

Institutional flow

+1.2 pts

74th pct

Earnings growth

+0.3 pts

57th pct

Shareholder dilution

+0.2 pts

53th pct

Revenue growth

-3.0 pts

35th pct

Latest change (2026-07-30): 70 → 72 · ↑ Earnings growth 30→67

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

BMY Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for BRISTOL MYERS SQUIBB CO (BMY), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BMY at 70.4/100 on a 32-signal composite quality model, placing it at rank #219 of 2,961 stocks — the top 10% of the AI-ranked universe. BMY scores in the top quartile across revenue scale (96.8), balance sheet strength (85.5), profitability (82.5). Areas of concern include revenue growth (34.9), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), BRISTOL MYERS SQUIBB CO reports quarterly revenue of $13.0B, net income of $3.3B, free cash flow of $3.1B. Top institutional holders of BMY by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. BMY trades on the NYSE exchange and files with the SEC under CIK 14272. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BMY daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BRISTOL MYERS SQUIBB CO directly from SEC EDGAR. BRISTOL MYERS SQUIBB CO's 13F Pro composite quality score has ranged between 47 and 77 since 2021, currently 70.4 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about BRISTOL MYERS SQUIBB CO

Quirks, history, and lore behind BMY — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. pharmaceutical giant · large-cap · listed on NYSE · headquartered in New York City.
2
The Numbers
Annual revenue around $45 billion, with a blockbuster drug portfolio that has kept it in the top 10 pharma companies globally for decades.
3
The History
The result of a 1989 mega-merger between two storied American drug companies, one founded in the 1850s — making it older than the lightbulb.
4
The Secret
It pulled off one of pharma's biggest acquisition gambits by buying Celgene for $74 billion in 2019, a bet-the-company deal that raised plenty of eyebrows on Wall Street.
5
The Lore
Its cancer drug Opdivo and blood thinner Eliquis are household names in oncology wards and cardiology clinics — together they generate the bulk of the company's sales.
6
The Giveaway
Three surnames walked into a boardroom — a Bristol, a Myers, and a Squibb — and somehow all three made it onto the door.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving BMY's Business? Latest 10-Q Breakdown

✓ 33/33 datapoints verified

AI-extracted from BRISTOL MYERS SQUIBB CO's 10-Q filed 2026-07-30 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Q2 revenue rose 6% to $12,973 million as the Growth Portfolio gained 15% and Eliquis 22%, while GAAP EPS jumped to $1.62 from $0.64.

Biggest Revenue Drivers

Growth Portfolio$7,560M+15% YoY

Higher demand and higher average net selling prices across the Growth Portfolio

Legacy Portfolio$5,422M-4% YoY

Impact of generics across the remainder of the Legacy Portfolio, partly offset by Eliquis

Biggest Revenue Drivers

Total revenue: $12,973M+6% YoY

Growth Portfolio$7,560M+15% YoY

Higher demand and higher average net selling prices across the Growth Portfolio

Within Growth Portfolio

Opdivo$2,485M-3% YoY

Lower U.S. demand reflecting greater utilization of Opdivo Qvantig

Legacy Portfolio$5,422M-4% YoY

Impact of generics across the remainder of the Legacy Portfolio, partly offset by Eliquis

Within Legacy Portfolio

Eliquis$4,481M+22% YoY

Higher demand and higher U.S. average net selling prices, as a U.S. list price reduction lowered rebates

Revlimid$425M-49% YoY

Lower U.S. demand as a result of generic erosion, partially offset by higher average net selling prices

Largest Expense Items

Cost of products sold$3,726M+11% YoY

Primarily due to higher alliance profit sharing

Research and development$2,959M+15% YoY

Higher IPRD impairment charges and the $220 million priority review voucher purchase, partly offset by productivity savings

Selling, general and administrative$1,826M+7% YoY

Higher investments in new product launches, partially offset by strategic productivity initiative savings

Amortization of acquired intangible assets$437M-47% YoY

Lower amortization for Pomalyst, whose acquired marketed product right was fully amortized in fourth quarter 2025

Margins: The filing gives no margin metric, but cost of products sold grew 11% versus 6% revenue growth on higher alliance profit sharing. Total GTN adjustments fell to 30% of gross sales from 46%.

Watch Items from the Filing

Receivables from the three largest U.S. customers were 71% of total trade receivables at June 30, 2026, versus 75% at December 31, 2025.
Legacy erosion is accelerating: Pomalyst/Imnovid -71%, Revlimid -49%, Sprycel -27%, Abraxane -47% as generics entered U.S. and EU markets.
Eliquis EU composition-of-matter patents and SPCs expire November 2026; UK generics already marketed, and IRA maximum fair price applied from January 1, 2026.
IPRD impairment charges of $420 million in the quarter ($830 million year-to-date) reflect a partial write-down of an oncology asset on recent clinical results.
New commitments: $600 million Hengrui upfront payable in Q3 2026 plus two $175 million anniversary payments, and $2.0 billion of BioNTech anniversary payments through 2028.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$13.0B

Net Income

Q2 2026

$3.3B

Free Cash Flow

Q2 2026

$3.1B

ROIC

Q2 2026

24.0%

D/E Ratio

Q2 2026

2.05

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-0.2% YoY

$48.19BFY 2025

FY22 $46.16BFY23 $45.01BFY24 $48.30BFY25 $48.19B

Net Income

+178.8% YoY

$7.05BFY 2025

FY22 $6.33BFY23 $8.03BFY24 $-8.95BFY25 $7.05B

EPS (Diluted)

+178.5% YoY

$3.46FY 2025

FY22 $2.95FY23 $3.86FY24 $-4.41FY25 $3.46

Total Assets

-2.8% YoY

$90.04BFY 2025

FY22 $96.82BFY23 $95.16BFY24 $92.60BFY25 $90.04B

Total Debt

-7.3% YoY

$51.33BFY 2025

FY22 $51.38BFY23 $48.64BFY24 $55.35BFY25 $51.33B

Op. Cash Flow

-6.8% YoY

$14.16BFY 2025

FY22 $13.07BFY23 $13.86BFY24 $15.19BFY25 $14.16B

Free Cash Flow

-7.9% YoY

$12.85BFY 2025

FY22 $11.95BFY23 $12.65BFY24 $13.94BFY25 $12.85B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$48.19B -0.2%	$48.30B +7.3%	$45.01B -2.5%	$46.16B -0.5%	$46.38B +9.1%	$42.52B
Net Income	$7.05B +178.8%	$-8.95B -211.5%	$8.03B +26.8%	$6.33B -9.5%	$6.99B +177.6%	$-9.02B
EPS (Diluted)	$3.46 +178.5%	$-4.41 -214.2%	$3.86 +30.8%	$2.95 -5.4%	$3.12 +178.2%	$-3.99
Total Assets	$90.04B -2.8%	$92.60B -2.7%	$95.16B -1.7%	$96.82B -11.4%	$109.31B -7.7%	$118.48B
Total Debt	$51.33B -7.3%	$55.35B +13.8%	$48.64B -5.3%	$51.38B -13.0%	$59.03B +3.5%	$57.02B
Operating Cash Flow	$14.16B -6.8%	$15.19B +9.6%	$13.86B +6.1%	$13.07B -19.4%	$16.21B +15.3%	$14.05B
Free Cash Flow	$12.85B -7.9%	$13.94B +10.2%	$12.65B +5.9%	$11.95B -21.6%	$15.23B +14.5%	$13.30B

Get alerted when BMY's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for BRISTOL MYERS SQUIBB CO including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of BMY

BlackRock, Inc.
$10.4B180,384,994 sh
VANGUARD CAPITAL MANAGEMENT LLC
$7.7B133,337,856 sh
STATE STREET CORP
$5.9B102,408,940 sh
JPMORGAN CHASE & CO
$4.2B71,713,442 sh
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
$3.9B67,595,177 sh
GEODE CAPITAL MANAGEMENT, LLC
$3.2B56,443,077 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$2.7B46,873,015 sh
NORGES BANK
$2.1B36,866,658 sh
BANK OF AMERICA CORP /DE/
$2.0B34,045,352 sh
PRICE T ROWE ASSOCIATES INC /MD/
$1.8B31,707,643 sh

Fund	Value	Shares
BlackRock, Inc.	$10.4B	180,384,994
VANGUARD CAPITAL MANAGEMENT LLC	$7.7B	133,337,856
STATE STREET CORP	$5.9B	102,408,940
JPMORGAN CHASE & CO	$4.2B	71,713,442
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	$3.9B	67,595,177
GEODE CAPITAL MANAGEMENT, LLC	$3.2B	56,443,077
VANGUARD PORTFOLIO MANAGEMENT LLC	$2.7B	46,873,015
NORGES BANK	$2.1B	36,866,658
BANK OF AMERICA CORP /DE/	$2.0B	34,045,352
PRICE T ROWE ASSOCIATES INC /MD/	$1.8B	31,707,643

Companies Similar to BMY

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

ABT

ABBOTT LABORATORIES

AI score

Very similar · 38 shared holders

Capital International Investors National Pension Service abrdn plc

PFE

PFIZER INC

AI score

Very similar · 53 shared holders

LSV ASSET MANAGEMENT National Pension Service Robeco Institutional Asset Management B.V.

ABBV

AbbVie Inc.

AI score

Very similar · 45 shared holders

NORDEA INVESTMENT MANAGEMENT AB Robeco Institutional Asset Management B.V.Capital International Investors

JNJ

JOHNSON & JOHNSON

AI score

Very similar · 42 shared holders

Independent Franchise Partners LLP NORDEA INVESTMENT MANAGEMENT AB Robeco Institutional Asset Management B.V.

MRK

Merck & Co., Inc.

AI score

Very similar · 45 shared holders

LSV ASSET MANAGEMENT NORDEA INVESTMENT MANAGEMENT AB Capital International Investors

AMGN

AMGEN INC

AI score

Very similar · 48 shared holders

PRIMECAP MANAGEMENT CO/CA/NORDEA INVESTMENT MANAGEMENT AB Capital International Investors

MDT

Medtronic plc

AI score

Very similar · 38 shared holders

M&G Plc National Pension Service PZENA INVESTMENT MANAGEMENT LLC

CVS

CVS HEALTH Corp

AI score

Very similar · 50 shared holders

PZENA INVESTMENT MANAGEMENT LLC LSV ASSET MANAGEMENT Capital International Investors

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put BMY on your watchlist

Track score changes the day BRISTOL MYERS SQUIBB CO files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is BMY a good stock to buy?

13F Pro's AI-powered analysis of BRISTOL MYERS SQUIBB CO (BMY) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BMY are available on the BMY stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. BMY is classified as a large company.

Which hedge funds own BMY?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BMY. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of BRISTOL MYERS SQUIBB CO's investment landscape.